Table 1.

Patient cohorts and drug escalation criteria

CohortsPralatrexate dose (i.v.)Bexarotene dosea (p.o.)
Cohort 115 mg/m2150 mg/m2
Cohort 2a15 mg/m2300 mg/m2
Cohort 2b10 mg/m2150 mg/m2
Cohort 310 mg/m2300 mg/m2
  • Abbreviation: p.o., orally.

  • aDose of bexarotene determined by guidelines per package insert.